CN116529265A - Cd73的抗原结合蛋白及其应用 - Google Patents

Cd73的抗原结合蛋白及其应用 Download PDF

Info

Publication number
CN116529265A
CN116529265A CN202180079159.5A CN202180079159A CN116529265A CN 116529265 A CN116529265 A CN 116529265A CN 202180079159 A CN202180079159 A CN 202180079159A CN 116529265 A CN116529265 A CN 116529265A
Authority
CN
China
Prior art keywords
seq
binding protein
amino acid
acid sequence
isolated antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180079159.5A
Other languages
English (en)
Chinese (zh)
Inventor
徐锦根
朱向阳
于海佳
韦小越
童玲
陈时
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huabo Biopharm Shanghai Co Ltd
Shanghai Huaota Biopharmaceutical Co Ltd
Original Assignee
Huabo Biopharm Shanghai Co Ltd
Shanghai Huaota Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huabo Biopharm Shanghai Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd filed Critical Huabo Biopharm Shanghai Co Ltd
Publication of CN116529265A publication Critical patent/CN116529265A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180079159.5A 2020-12-11 2021-12-10 Cd73的抗原结合蛋白及其应用 Pending CN116529265A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011445512 2020-12-11
CN2020114455120 2020-12-11
PCT/CN2021/136950 WO2022122004A1 (fr) 2020-12-11 2021-12-10 Protéine de liaison à l'antigène cd73 et son application

Publications (1)

Publication Number Publication Date
CN116529265A true CN116529265A (zh) 2023-08-01

Family

ID=81973100

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180079159.5A Pending CN116529265A (zh) 2020-12-11 2021-12-10 Cd73的抗原结合蛋白及其应用

Country Status (8)

Country Link
US (1) US20240026024A1 (fr)
EP (1) EP4261224A4 (fr)
JP (1) JP2023554326A (fr)
KR (1) KR20230119173A (fr)
CN (1) CN116529265A (fr)
AU (1) AU2021395129A1 (fr)
TW (1) TWI900705B (fr)
WO (1) WO2022122004A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118420709A (zh) * 2024-04-29 2024-08-02 南京鼓楼医院 靶向cd73的肿瘤抗原肽、疫苗及其制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4538293A1 (fr) * 2022-06-08 2025-04-16 Shanghai Huaota Biopharmaceutical Co., Ltd. Protéine de liaison à l'antigène bispécifique cd39/cd73 et son utilisation
TW202405018A (zh) * 2022-06-08 2024-02-01 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３抗體雞尾酒療法
CN120418292A (zh) * 2022-12-26 2025-08-01 百力司康生物医药(杭州)有限公司 抗cd73抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
JP7037359B2 (ja) * 2014-10-10 2022-03-16 イナート・ファルマ・ソシエテ・アノニム Ｃｄ７３遮断
KR102781223B1 (ko) * 2014-11-10 2025-03-12 메디뮨 리미티드 Cd73에 특이적인 결합 분자 및 이의 용도
TWI711630B (zh) * 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
WO2017064043A1 (fr) * 2015-10-12 2017-04-20 Innate Pharma Agents de blocage de cd73
AU2016366548C1 (en) * 2015-12-09 2024-07-25 Bioatla, Llc Humanized anti-CD73 antibodies
WO2017118613A1 (fr) * 2016-01-08 2017-07-13 Syddansk Universitet Anticorps bispécifiques ciblant cd73 humain
CA3016187A1 (fr) * 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Polytherapie avec des anticorps anti-cd73
WO2018013611A1 (fr) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anticorps anti-cd73
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
UA126571C2 (uk) * 2017-01-24 2022-11-02 Ай-Маб Байофарма Юес Лімітед Антитіло до cd73 та його застосування
EP3630830A1 (fr) * 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Nouvel anticorps anti-cd73 et utilisations associées
BR112020016049A2 (pt) * 2018-03-09 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anti-cd73 e seus usos
EP3569618A1 (fr) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisation d'anticorps cd73
AU2019377454A1 (en) * 2018-11-05 2021-05-27 Corvus Pharmaceuticals, Inc. B-cell activating CD73 antibodies
EP3882268A4 (fr) * 2018-11-12 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-cd73, fragment de liaison à l'antigène de celui-ci et son utilisation
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
TWI790445B (zh) * 2019-06-06 2023-01-21 大陸商北京加科思新藥研發有限公司 對cd73具有特異性的結合分子及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118420709A (zh) * 2024-04-29 2024-08-02 南京鼓楼医院 靶向cd73的肿瘤抗原肽、疫苗及其制备方法和应用

Also Published As

Publication number Publication date
AU2021395129A1 (en) 2023-07-06
TWI900705B (zh) 2025-10-11
EP4261224A4 (fr) 2025-04-23
US20240026024A1 (en) 2024-01-25
TW202222840A (zh) 2022-06-16
JP2023554326A (ja) 2023-12-27
EP4261224A1 (fr) 2023-10-18
WO2022122004A1 (fr) 2022-06-16
KR20230119173A (ko) 2023-08-16

Similar Documents

Publication Publication Date Title
TWI801862B (zh) 抗ｔｉｇｉｔ的抗體、其製備方法和應用
CA2798285C (fr) Anticorps dirige contre l'antigene carcino-embryonnaire et ses utilisations
WO2020043188A1 (fr) Anticorps anti-cd47 et son utilisation
TWI900705B (zh) Ｃｄ７３的抗原結合蛋白及其應用
WO2021170082A1 (fr) Anticorps anti-cd47/anti-pd-l1 et ses utilisations
US20240067747A1 (en) Cd73-binding protein and use thereof
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
US20240190986A1 (en) Mesothelin binding molecule and application thereof
WO2021160138A1 (fr) Protéine de liaison à l'antigène de l'anti-récepteur du facteur de croissance épidermique et son application
WO2023138638A1 (fr) Protéine bispécifique de liaison à l'antigène contre tigit et pd-l1 et son utilisation
JP2024503425A (ja) 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用
CN113264999B (zh) 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
WO2022257868A1 (fr) Protéine de liaison à l'antigène contre l'albumine sérique humaine
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途
EP4317182A1 (fr) Protéine de liaison à l'antigène ciblant la protéine hémolysine de streptococcus pneumoniae et son utilisation
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
CN114426580B (zh) 抗csf-1r抗体及其产品、方法和用途
WO2023236968A1 (fr) Protéine de liaison à l'antigène bispécifique cd39/cd73 et son utilisation
JP2024508048A (ja) Ｓｉｇｌｅｃ－１５結合タンパク質の調製およびその使用
WO2025140296A1 (fr) Anticorps anti-dll3 ou fragment de liaison à l'antigène de celui-ci, et son utilisation
WO2025185738A1 (fr) Protéine de liaison à l'antigène ciblant cxcr3 et son utilisation
CN119350502A (zh) 靶向fap的抗原结合蛋白及其应用
WO2023138643A1 (fr) Protéine de liaison à l'antigène cd39 et son utilisation
CN118165107A (zh) 结合tigit的抗体分子
CN115572330A (zh) 一种特异性抗体及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination